Dr. Hirmand, Mr. Selby, and Dr. Seely report being employees of and holding stock or stock options in Medivation. ); Institut Gustave Roussy, University of Paris Sud, Villejuif, France (K.F. Peer-reviewed journal featuring in-depth articles to accelerate the transformation of health care delivery.Information, resources, and support needed to approach rotations - and life as a resident.Valuable tools for building a rewarding career in health care.Information and tools for librarians about site license offerings.The authorized source of trusted medical research and education for the Chinese-language medical community.The most trusted, influential source of new medical knowledge and clinical best practices in the world.Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyKaplan–Meier Estimates of Primary and Secondary End Points in the Intention-to-Treat Population.Subgroup Analyses of Hazard Ratios for Death in the Two Study Groups.Secondary End Points Related to Response and Disease Progression.Kaplan–Meier Estimates of Primary and Secondary End Points in the Intention-to-Treat Population.Subgroup Analyses of Hazard Ratios for Death in the Two Study Groups.Secondary End Points Related to Response and Disease Progression. A phase 1b/2a study of ZEN-3694 plus enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) demonstrated acceptable tolerability and potential efficacy of the combination in patients with androgen signaling inhibitor (ASI)-resistant mCRPC. The primary efficacy end point was a between-group comparison of the time from randomization to death from any cause (overall survival) in the intention-to-treat population (all randomly assigned patients). The use of prednisone or other glucocorticoids was permitted but not required, and the study drug was given without regard to food intake. Enzalutamide was previously approved for the treatment of patients with metastatic CRPC.Approval in patients with NM-CRPC was based on a randomized, multicenter clinical trial (PROSPER, NCT020032924), that randomized 1,401 patients 2:1 to either enzalutamide 160 mg orally once daily or placebo orally once daily. Dr. Saad reports receiving consulting fees and payment for the development of educational presentations from Astellas Pharma, Janssen Pharmaceuticals, and Sanofi-Aventis and consulting fees from Medivation. Enzalutamide was initially approved in 2012 for use in patients with mCRPC who had previously received docetaxel. Results: In a population of 115 chemotherapy-naïve mCRPC patients, adopting enzalutamide had an annual incremental budget impact of $510,641 ($4,426 PPPY, $369 PPPM, and $0.04 PMPM). The investigators also suggested denosumab or zoledronic acid for fracture prevention. Results were most sensitive to enzalutamide drug cost, size of the chemotherapy-naïve mCRPC patient population, and enzalutamide adoption rate. A phase 1b/2a study of ZEN-3694 plus enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) demonstrated acceptable tolerability and potential efficacy of the combination in patients with androgen signaling inhibitor (ASI)-resistant mCRPC.“Resistance to androgen receptor-targeting agents is inevitable in metastatic, castration-resistant prostate cancer,” co-senior study author Joshi Alumkal, MD, who leads the Prostate and Genitourinary Medical Oncology Section at the U-M Rogel Cancer Center, said in a press release.In total, 30 (40%) patients were resistant to abiraterone, 34 (45.3%) to enzalutamide, and 11 (14.7%) to both. An official website of the United States government: The Eastern Cooperative Oncology Group (ECOG) grades the performance status of patients with respect to activities of daily living, with 0 indicating that the patient is fully active and able to carry out all predisease activities without restriction; 1 indicating that the patient is restricted in physically strenuous activity but is ambulatory and able to carry out work of a light or sedentary nature; and 2 indicating that the patient is ambulatory and up and about for more than 50% of waking hours and is capable of self-care but unable to carry out work activities.